Products for Research Use Only
RegisterLogin

Boceprevir (Standard)

CAT: 0804-HY-10237R-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-10237R-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Boceprevir (Standard) is the analytical standard of Boceprevir. This product is intended for research and analytical applications. Boceprevir (EBP 520) is a potent, highly selective, orally bioavailable HCV NS3 protease inhibitor with a Ki of 14 nM in both enzyme assay and an EC90 of 350 nM in cell-based replicon assay[1][2][3][4][5]. Boceprevir inhibits SARS-CoV-2 3CLpro activity[6].
CAS Number
394730-60-0
Product Name Alternative
EBP 520 (Standard) ; SCH 503034 (Standard)
UNSPSC
12352005
Target
HCV; HCV Protease; Reference Standards; SARS-CoV
Type
Reference Standards
Related Pathways
Anti-infection; Metabolic Enzyme/Protease; Others
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/boceprevir-standard.html
Smiles
O=C(N1[C@@H]([C@@]2([H])C(C)([C@]2(C1)[H])C)C(NC(C(C(N)=O)=O)CC3CCC3)=O)[C@@H](NC(NC(C)(C)C)=O)C(C)(C)C
Molecular Formula
C27H45N5O5
Molecular Weight
519.68
References & Citations
[1]Njoroge FG, et al. Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection. Acc Chem Res. 2008 Jan;41 (1) :50-9.|[2]Yao M, et al. Conditional Inducible Triple-Transgenic Mouse Model for Rapid Real-Time Detection of HCV NS3/4A ProteaseActivity. PLoS One. 2016 Mar 4;11 (3) :e0150894.|[3]Coilly A, et al. Practical management of boceprevir and immunosuppressive therapy in liver transplant recipients with hepatitis C virus recurrence. Antimicrob Agents Chemother. 2012 Nov;56 (11) :5728-34.|[4]Berenguer M, et al. New developments in the management of hepatitis C virus infection: focus on boceprevir. Biologics. 2012;6:249-56.|[5]Burton MJ, et al. Telaprevir and boceprevir in african americans with genotype 1 chronic hepatitis C: implications for patients and providers. South Med J. 2012 Aug;105 (8) :431-6.|[6]Qi Sun, et al. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. Signal Transduct Target Ther. 2021 May 29;6 (1) :212.
Shipping Conditions
Room temperature
Scientific Category
Reference Standards

Related Products

CatalogName
HY-10237-01Boceprevir
HY-10237S-01Boceprevir-d9
HY-W778501-012-Dihydro Boceprevir-d9
HY-P2274RArgifin (Standard)
HY-N9362REmodinanthrone (Standard)
HY-N7948RIsomaltotetraose (Standard)
HY-N7640RDeoxylimonin (Standard)
HY-N7617RToralactone (Standard)
HY-N7541RAntrodin A (Standard)
HY-N6739RBeauvericin (Standard)

Alternative Products

CatalogName
A3261-10Boceprevir

Popular Products